Tirzepatide and kidney outcomes

A 2026 real-world cohort study compared kidney outcomes after starting GLP-1 receptor agonists or tirzepatide with outcomes after starting finerenone in adults with type 2 diabetes and moderate chronic kidney disease. In the matched cohort, the GLP-1/GIP group had a lower relative hazard of the study's composite kidney endpoint. The estimate for the absolute risk difference, however, included no difference^[1]. That distinction matters: this observational result is not a finding that one medicine should replace another for an individual patient.

What the cohort compared

The investigators used the TriNetX global network and reviewed records from July 2021 through November 2025. They identified adults with type 2 diabetes and stage 3 or 4 chronic kidney disease who began either a GLP-1/GIP receptor agonist or finerenone. GLP-1/GIP receptor agonists in the paper's terminology include tirzepatide, which acts at GIP and GLP-1 receptors. Finerenone is a nonsteroidal mineralocorticoid receptor antagonist used in kidney and cardiovascular risk management for eligible people with type 2 diabetes and chronic kidney disease^[2].

After 1:1 propensity-score matching, the analysis included 4,554 people. Their mean age was 70.7 years, 43.3% were women, and the mean estimated glomerular filtration rate, or eGFR, was 39.4 mL/min/1.73 m2. These details define the population behind the result. They do not show that the findings apply unchanged to people with earlier kidney disease, advanced kidney failure, a different diabetes profile, or a different treatment history^[1].

The kidney endpoint and the reported numbers

The primary endpoint combined end-stage kidney disease, stage 5 chronic kidney disease, or dialysis initiation. During follow-up of up to 2.5 years, the endpoint occurred in 110 people, or 4.8%, in the GLP-1/GIP group and 136 people, or 6.0%, in the finerenone group. The reported hazard ratio was 0.71 with a 95% confidence interval from 0.55 to 0.91^[1]. A hazard ratio describes the relative pattern of events over time; it does not state a personal likelihood of kidney failure.

The authors also reported a 2.5-year absolute risk difference of minus 1.14 percentage points, with a 95% confidence interval from minus 2.45 to 0.17 percentage points. Because that interval crossed zero, the study did not provide evidence of a difference in absolute risk at conventional statistical thresholds. This is why the paper's conclusion describes lower relative hazard without evidence of a difference in absolute risk^[2]. Both measures belong in any reading of the finding.

How eGFR slope fits into the finding

eGFR is an estimate used to track kidney filtration over time. The study compared both a total eGFR slope from zero to 2.5 years and a chronic slope from 0.5 to 2.5 years. The GLP-1/GIP group had a 1.04 mL/min/1.73 m2/year difference in the total slope, with a confidence interval from 0.32 to 1.75. For the chronic slope, the between-group difference was minus 0.08 mL/min/1.73 m2/year, with a confidence interval from minus 1.27 to 1.12^[1].

The difference between those two analyses is important. A total slope can reflect changes soon after treatment begins, while the chronic-slope comparison was designed to examine the later period. The paper reports no evidence of a chronic eGFR-slope difference. It therefore does not establish that tirzepatide, or the wider GLP-1/GIP group, slows long-term kidney-function decline more than finerenone in this population.

Why this cannot settle a treatment choice

This was a retrospective, nonrandomized study, rather than a trial that assigned treatments at random. Propensity-score matching can make measured characteristics more comparable, but it cannot remove differences that were not measured or incompletely captured. The authors specifically note that baseline albuminuria data were missing for most participants. Albuminuria is a central marker in chronic kidney disease assessment, so under-sampling it leaves room for residual confounding^[1].

The comparison also groups GLP-1 receptor agonists and tirzepatide together. It does not provide a randomized, medicine-by-medicine comparison of tirzepatide with finerenone. Nor does it test a treatment plan that combines medicines, changes background therapy, or selects patients by albuminuria. Readers looking for background on the dual-receptor medicine can review the tirzepatide evidence overview, but a clinician who knows the person's kidney function, urine findings, blood pressure, other medicines, and goals should interpret treatment options.

What this study adds to the kidney conversation

The study adds a matched real-world comparison to a question that randomized trials have not fully answered: how kidney outcomes look after initiation of GLP-1-based therapy or finerenone in older adults with type 2 diabetes and moderate chronic kidney disease. Its sensitivity analyses were reported as consistent, which supports the stability of the observed association within the database. Still, association is not proof of a treatment effect, and it is not a dosing or treatment recommendation.

For people already taking or considering tirzepatide, the practical message is narrower than a headline comparison. Kidney disease care depends on diagnosis, laboratory trends, albuminuria, cardiovascular risk, tolerability, and other therapies. This cohort provides a signal worth discussing with a qualified clinician; it does not identify a preferred regimen for any one person.

This article is for informational purposes only and does not constitute medical advice. Do not start, stop, or change a prescribed medicine based on this article.